MitoCareX Bio is a drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with their proteins of interest, it uses its advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. The selected hit candidates are then progressed along the pre-clinical path.
Cumulative Funding Raised Over Time ($)
Employees Over Time
MitoCareX Bio Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Feb 26, 2025
www.nasdaq.com
N2OFF, Inc. Enters Agreement to Acquire MitoCareX Bio Ltd. to Expand Cancer Therapeutics Portfolio
null
Jan 6, 2025
www.globenewswire.com
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results